<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04934865</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2020-13</org_study_id>
    <nct_id>NCT04934865</nct_id>
  </id_info>
  <brief_title>Real Life Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG</brief_title>
  <acronym>REAL-MOOV-LUNG</acronym>
  <official_title>Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of patient's proportion, whose management care has been modified at least once and&#xD;
      specially by Moovcare® Lung application at 12 and 24 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective of the study:&#xD;
&#xD;
      The primary objective is a clinical one and is to evaluate the proportion of patients, whose&#xD;
      management care has been modified at least once and specially by Moovcare® Lung application&#xD;
      at 12 and 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients.</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of patients whose care management was modified at least once and specifically by Moovcare® Lung application at months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients.</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients whose care management was modified at least once and specifically by Moovcare® Lung application at 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical aspects : date of consultation.</measure>
    <time_frame>24 months</time_frame>
    <description>Interval between the date of early consultation or early scan and the date of the scheduled consultation or scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical aspects : Number of unscheduled hospitalizations.</measure>
    <time_frame>24 months</time_frame>
    <description>Number of unscheduled hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical aspects : Duration of unscheduled hospitalizations.</measure>
    <time_frame>24 months</time_frame>
    <description>Duration of unscheduled hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical aspects : Number of overall hospitalizations.</measure>
    <time_frame>24 months</time_frame>
    <description>Number of overall hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical aspects : Duration of overall hospitalizations.</measure>
    <time_frame>24 months</time_frame>
    <description>Number of overall hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical aspects : Quality of life.</measure>
    <time_frame>Every 3 months until 24 months</time_frame>
    <description>Quality of life criteria with EORTC QLQ-C30 questionnaire scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical aspects : Overall survival over the entire follow-up.</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival over the entire follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organizational aspects : number of stakeholders</measure>
    <time_frame>24 months</time_frame>
    <description>Number of stakeholders on the application, number of stakeholders specifically recruited for the application and type of stakeholders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organizational aspects : Time for each investigating center</measure>
    <time_frame>24 months</time_frame>
    <description>Calculation of the time spent to set up the protocol and the application for each investigating center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organizational aspects : Functioning and processing of alerts :</measure>
    <time_frame>24 months</time_frame>
    <description>Time spent to register patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organizational aspects : Functioning and processing of alerts :</measure>
    <time_frame>24 months</time_frame>
    <description>Total number of alerts, rate of alerts handled by the health care team.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organizational aspects : Functioning and processing of alerts :</measure>
    <time_frame>24 months</time_frame>
    <description>Number of alerts that led to an early consultation: processing time, type of provider(s), number of alerts that led to further investigation and the type of investigation: processing time, type of provider(s), rate of alerts that led to a change in management.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organizational aspects : Functioning and processing of alerts :</measure>
    <time_frame>24 months</time_frame>
    <description>Relevant post-alert management time, as well as the number of stakeholders on the application, type of stakeholders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organizational aspects : Patient satisfaction.</measure>
    <time_frame>3, 6, 12, 18 and 24 months of use of the application</time_frame>
    <description>The degree of patient satisfaction will be evaluated with a satisfaction questionnaire. A form to be filled in after 3, 6, 12, 18 and 24 months of use of the application.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organizational aspects : Satisfaction of the care teams at 6 months follow-up.</measure>
    <time_frame>6 months follow-up</time_frame>
    <description>Physician satisfaction: the satisfaction of all doctors involved will be evaluated with a questionnaire to be filled in (Questionnaire Satisfaction Médecins).&#xD;
Staff satisfaction: the satisfaction of all staff involved (coordinating nurses, secretaries or other categories of staff) will be assessed with a questionnaire to be filled in (Questionnaire Satisfaction Collaborateur).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organizational aspects : Patient compliance.</measure>
    <time_frame>24 months</time_frame>
    <description>The compliance will be evaluated by the ratio between the number of completed questionnaires and the invitation's number sent to complete them. Reasons of impossible connection (must be documented on medical records) will be subtracted from the calculation.&#xD;
The number of patients who voluntary abandoned the use of Moovcare® Lung medical device will be reduced considered as non-compliant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organizational aspects : all secondary outcome measures</measure>
    <time_frame>12 months of follow-up</time_frame>
    <description>above criteria will be assessed at 12 months of follow-up. This analysis will be done one year after inclusion of the last patient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Patients treated for their lung cancer and Moovcare® Lung follow-up.</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Patients treated for their lung cancer.</intervention_name>
    <description>In addition to the weekly Moovcare® Lung follow-up, patients will benefit from standard oncological follow-up at the discretion of their oncologist according to standard recommendations for 2 years. Questionnaires will be completed at different times as mentioned below on the global study scheme and Flowchart.&#xD;
In an active treatment situation, the pace of consultations will be adapted to the pace of treatment administration, according to standard recommendations. It may be lengthened in the absence of a clinical application or biological alert at the discretion of the investigator.</description>
    <arm_group_label>Patients treated for their lung cancer and Moovcare® Lung follow-up.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with lung cancer at any diagnostic stage and histology.&#xD;
&#xD;
          2. Patient willing to use the follow-up setting with Moovcare® Lung apps.&#xD;
&#xD;
          3. Age ≥ 18 years.&#xD;
&#xD;
          4. Patient received anti-cancer treatment (surgery, chemotherapy, radiation (stereotaxy&#xD;
             or not) or radio-chemotherapy association ended less than 8 weeks (Cohort 1&#xD;
             post-treatment); or during maintenance treatment or consolidation by chemotherapy or&#xD;
             targeted therapy, or by immunotherapy initiated less than 8 weeks (Cohort 2 during&#xD;
             treatment).&#xD;
&#xD;
          5. Imaging tumor evaluation less than 8 weeks showing disease control (response or&#xD;
             stability according to RECIST 1.1 criteria).&#xD;
&#xD;
          6. Patient with symptomatic score on Moovcare® Lung apps less than 7.&#xD;
&#xD;
          7. Patient (or relatives) with internet access, a personnal e-mail box and a smartphone.&#xD;
&#xD;
          8. Patient with social security affiliation.&#xD;
&#xD;
          9. Signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with progression after the first evaluation of initial treatment.&#xD;
&#xD;
          2. Pregnancy and breast-feeding.&#xD;
&#xD;
          3. Patient under tutorship or guardianship.&#xD;
&#xD;
          4. Dementia, mental alteration or psychiatric pathology influencing patient consent&#xD;
             procedure and/or protocol observance and study follow-up.&#xD;
&#xD;
          5. Patient enable to protocol follow-up for psychological, social, familial or&#xD;
             geographical reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolas GIRARD, Pr</last_name>
    <phone>01 44 32 46 77</phone>
    <email>nicolas.girard2@curie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cyrine EZZILI, PhD</last_name>
    <phone>01 47 11 16 57</phone>
    <email>cyrine.ezzili@curie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ico Angers</name>
      <address>
        <city>Angers</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sandrine HIRET, MD</last_name>
      <phone>0240679978</phone>
      <email>sandrine.hiret@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sandrine HIRET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Argenteuil</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laure BELMONT, MD</last_name>
      <email>laure.belmont@ch-argenteuil.fr</email>
    </contact>
    <investigator>
      <last_name>Laure BELMONT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Public du Cotentin</name>
      <address>
        <city>Cherbourg</city>
        <zip>50100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laure KALUZINSKI, MD</last_name>
      <email>laure.kaluzinski@ch-cotentin.fr</email>
    </contact>
    <investigator>
      <last_name>Laure KALUZINSKI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Franco Britannique</name>
      <address>
        <city>Levallois-Perret</city>
        <zip>92300</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nathalie PEREZ-STAUB</last_name>
      <phone>0147591915</phone>
      <email>nathalie.perez-staub@ihfb.org</email>
    </contact>
    <investigator>
      <last_name>Nathalie PEREZ-STAUB, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric DANSIN, MD</last_name>
      <email>e-dansin@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Eric DANSIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Limoges - Site de François CHENIEUX</name>
      <address>
        <city>Limoges</city>
        <zip>87039</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Xavier ZASADNY, MD</last_name>
      <phone>0555454800</phone>
      <email>xz@imagemed-87.com</email>
    </contact>
    <investigator>
      <last_name>Xavier ZASADNY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent GREILLIER, PH</last_name>
      <phone>0491965901</phone>
      <email>laurent.greillier@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent GREILLIER, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-George</name>
      <address>
        <city>Nice</city>
        <zip>06100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Ophélie CASSUTO, MD</last_name>
      <phone>0492145454</phone>
      <email>drcassuto@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ophélie CASSUTO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas GIRARD, PH</last_name>
      <phone>0144324677</phone>
      <email>nicolas.girard2@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas GIRARD, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de PAU</name>
      <address>
        <city>PAU</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick Aldo RERNAULT, MD</last_name>
      <phone>0559724123</phone>
      <email>aldo.renault@ch-pau.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick Aldo RENAULT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Stéphane HOMINAL, MD</last_name>
      <phone>04 50 63 66 03</phone>
      <email>shominal@ch-annecygenevois.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane HOMINAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Saint-cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Ange MASSIANI, MD</last_name>
      <phone>0147111519</phone>
      <email>marieange.massiani@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Ange MASSIANI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bertrand MENNECIER, MD</last_name>
      <phone>0369550905</phone>
      <email>bertrand.mennecier@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Bretrand MENNECIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Schumann</name>
      <address>
        <city>Vantoux</city>
        <zip>57070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

